AGENDA
AAVPT Annual Business Meeting
Tuesday, May 23, 2023
7-8:30 am Eastern Time

In Person: White Flint Amphitheater at the Bethesda North Marriott Hotel & Conference Center

Join Zoom Meeting
https://us02web.zoom.us/j/85827080982
Meeting ID: 858 2708 0982
One tap mobile
+13017158592,,85827080982# US (Washington DC)
+13052241968,,85827080982# US

Dial by your location
   +1 301 715 8592 US (Washington DC)
   +1 312 626 6799 US (Chicago)
   +1 929 436 2866 US (New York)
   +1 669 900 6833 US (San Jose)
   +1 253 215 8782 US (Tacoma)
   +1 346 248 7799 US (Houston)
Meeting ID: 858 2708 0982
Find your local number: https://us02web.zoom.us/u/kcfjbYvr5O

Welcome (Jonathan Hare)
Approve minutes from 2021 Annual Business Meeting
Reports
   President (Jonathan Hare)
   Secretary (Jen Davis)
   Treasurer/Comptroller (Luke Wittenburg, Scott Brown)
   Veterinary Pharmacology Research Foundation (Jane Owens)
   Journal of Veterinary Pharmacology and Therapeutics (Katrina Mealey)
   Other reports
Vote to accept reports
Combating Illicit Xylazine Use Act
Walk-in Items
Close meeting
2023 Business meeting minutes


President’s report

We have made some progress on the recommendations of the LRPC. A communications committee was formed to modernize and update our logo, which is on the ‘swag’ handed out at the meeting.

Thank you to those that have helped during his tenure, including the officers of AAVPT.

A motion to approve past business meeting minutes was called for. Dr. Lainesse moved, Dr. Fajt seconded. All in favor.

Secretary’s report

- Membership is similar to other years.
- Please nominate yourself or someone else for Distinguished Fellow or Fellow.
- Pay your dues.
- We are currently looking to hire a new Executive Assistant. Anyone that knows anyone interested, please forward the request for applications to them.
- Elections were open at the time of the Business meeting, but will close before the end of the Biennial.
- Committee membership/leadership positions are available for volunteers.

Treasurer and Comptroller reports

Finances are detailed in the submitted reports.

As we are a non-profit organization, we have been attempting to bring our balance down into the range of $100-125,000. The balance goes towards VPRF, the Biennial, other costs. Recommendations are to invest in VPRF in the range of $15-30,000. The current balance does no include expenses incurred from the 2023 Biennial.

RH – suggested on a motion for VPRF donation at the business meeting.

JH – suggested waiting for the finances to balance after the Biennial.

VF – this is typically the duty of the EC

RH – understood, but the membership can have some input as well

VPRF

Thanks to the attendees, we generated over $6k in revenue at the auction the previous evening.

Changes in the VPRF board: Scott Brown is now on the board in a fundraising position; Jay Donecker is taking over for Dan Gingerich as Treasurer.

As of this year, the VPRF have funded > $450,000 in grants (including one this year in elephants!). This year will also include funding for a Student Fellowship. MS or PhD students will be able
to apply. They must be enrolled in good standing at a recognized school for at least 1 year. They also must be student members or members. The fellowship will fund up to $10k in support and can be used for various things relating to work as a student.

Dr. Owens wanted to thank everyone for their donations. AAVPT remains the largest donor.

Several board members will be going to the upcoming EAVPT meeting and they will promote applications coming from EAVPT and suggest the potential for targeted grants through their organization.

RH – Made motion at this time that the AAVPT EC consider the donation to continue to support the VPRF. VF seconded, all approved.

JVPT – see attached report

Xylazine

Presentation from Dr. Hornicker on the issues regarding illicit use of xylazine in illegal drugs was given at the Biennial the preceding day.

Dr. Hare proposed a motion to support the AVMA’s efforts with the following statement:

‘The American Academy of Veterinary Pharmacology and Therapeutics offers its support for the Combating Illicit Xylazine Act (H.R. 1839/S.993) as an endorsing organization”

VF: AABP/AASRP are also on board with this act, as many bovine and small ruminant practitioners do not have DEA licenses and without this act, xylazine would no longer be available. They have no other drug alternatives.

SB: What does it mean to offer ‘support’? Support is a broad word and could include financial aid. Suggested ‘endorse’.

RH: supported amending support to endorse. Xylazine is a very important drug for Zoo and Wildlife medicine since it is not currently scheduled and does not require special storage, therefore it is readily available in emergency situations.

VF: Suggested the wording be changed to: The AAVPT endorses the Combating Illicit Xylazine Act

AL: Has anyone looked for unintended consequences? Is there anything in the fine print?

RH: Has read the act in full. The wording will change as it goes through Congress.

JD: Has anyone talked to the AAEP? (Response: Yes – they will also support.)

JH: Called for a vote on the amended statement: “The American Academy of Veterinary Pharmacology and Therapeutics endorses the Combating Illicit Xylazine Act (H.R. 1839/S.993).”

All in favor – motion passed. Jonathan will convey to the AVMA rep.

Walk-in items

Our president-elect nomination (Robbin Koenig) is currently an Associate Fellow. The bylaws state she must be a Fellow in order to be President. Dr. Hare stated Dr. Koenig is well qualified for Fellow based on her experience in Pharmacology and previous service on AAVPT Committees. Suggested she be
put up for Fellow status. This requires two nominations: RH is one; VF second. A vote of 80% of the EC is needed to approve her fellowship. All members that were present voted to approve. Dr. Koenig was promoted to Fellow status.

Motion to adjourn and second received. Meeting closed.
AVPT President’s Report 2023

When I was first elected to the Executive Committee, as Treasurer in 2015, I remember Anthony Lucas was outgoing President. This was in Colorado. He said words to the effect that he started his tenure with all of these things he wanted to do, but time slipped by and he didn’t get done nearly what he hoped.

I get it!

It seems like I’ve been on a never-ending treadmill of organizing Biennials. Other business, including addressing the recommendations of the Long-Range Planning Committee, has fallen to the side a bit.

As I leave the presidency, I’d like to see us renew our commitment to the modernization of the AAVPT as envisioned by the LRPC. As we have seen with some of the speakers at this symposium, the world of pharmacology grows ever more rich and complex. We have an important role to play and our broad tent of industry, academia and regulatory scientists has an important voice in the issues affecting our profession.

We’ve taken some baby steps. With the guidance of the Communications Committee we’ve updated and modernized our logo. Hopefully that will spur us on to a reevaluation and refinement of our purpose during the term of the next council. I look forward to continuing to be a part of this!

I’d like to give some thanks. Jen Davis keeps the lights on at the AAVPT. She does so much of the behind-the-scenes work that allows our meetings to run smoothly, our elections to be held, and has tirelessly worked on our Biennials. Luke Wittenburg and Scott Brown have made sure we are financially responsible and in good standing. The
ideas of our incoming president, Michela Cantiello, and the gruff wisdom of our past president, Rob Hunter, have always been appreciated. And to all who have worked as councilors or committee members, thanks for you input.

Enjoy the rest of the meeting!

Jonathan E. Hare, DVM, PhD, Dipl ACVCP
Telemark Veterinary Consulting Inc.

AAVPT Secretary’s Report 2023

Current membership is 84 paid members, which is similar to other years by the 6 month mark. If you know of anyone interested in veterinary pharmacology who is not already a member, please direct them to the website and encourage them to become members.

We are also still soliciting calls for upgraded membership. If you know someone deserving of Fellow Membership or Distinguished Fellow Membership, please feel free to nominate them. Self-nominations are accepted with appropriate references.

If you have not paid your annual dues yet, please login to the website (aavpt.org) to renew your membership and update your information. Otherwise, look for another membership renewal reminder at the end of the year. We are continuing to streamline the process of dues renewal and notification. This process will be enhanced once we hire another executive assistant. This position is currently open and available for immediate hire. A position description is included and members are encouraged to forward to anyone that may be interested.

Remember, members can renew their memberships, subscribe to the Journal of Veterinary Pharmacology and Therapeutics at a reduced rate, as well as donate to AAVPT and VPRF year-round, rather than just once a year. Go to www.aavpt.org.
Elections are currently underway and the ballot will be open through the Biennial. Go to https://www.aavpt.org/surveys/?id=AAVPT_Ballot_2023 to cast your vote. Only paid members of Associate Fellow, Fellow or Distinguished Fellow status can vote. We are still looking for candidates for the Treasurer position. If you are interested, please nominate yourself or someone else.

Drs. Maya Scott-Garrard and Sarah Wagner will be our representatives on AVMA’s Animal Agriculture Liaison Committee. If you are interested in becoming more active in AAVPT and would like to join a committee, please let me know. We need the help of all our members if we want our organization to grow and continue to be relevant. Current active committees listed in the bylaws include:

1. Finance and Budget Committee
2. Membership and Bylaws Committee
3. Program Committee
4. Education Committee
5. Awards Committee
6. AAVPT Newsletter Committee

We have made a concerted effort to include new members in our listserv and to update the information on our current members. If your email has changed, please send a note to aavptsec@gmail.com and I will fix it for you!

Thanks to all our members for their continuing support!
Jennifer L Davis, DVM, PhD, DACVCP, DACVIM

**AAVPT Treasurer’s Report 2023**

August 1, 2022 through May 15, 2023
Checking account balance as of 05/15/2023 is $51,054.71.
Revenue since last report (August 1st, 2021) as follows:
• $4,380 from membership fees (this includes amounts that were added to dues payments for VPRF donations of $100).
• $4,900 in Biennial Sponsorships
• $48,480 in total Biennial event related revenue (registrations)

Expenses since last report (July 2022) as follows:
• $1,982.95 in bank, credit card, corporation registration, Zoom account fees
• $5,977.84 for services (website hosting, logo design, P.O. Box)
• $30,100 in VPRF donations
• $500 in poster presentation award.

Investment accounts:
• One-time transfer of $30,000 was made from investment account into checking account on 09/07/2022.

Final revenue and expenses from the Biennial not yet available and will be included in the next Treasurer’s report.

Luke Wittenburg, DVM, PhD, DACVCP
Treasurer
May 18th, 2023

AAVPT Comptroller’s Report 2023
January 2022 – April 2023 Reporting Range
Report Date: May 4, 2023

The Raymond James AAVPT investment fund has a current balance (April 28, 2023) of $135,861.94, down from the balance at the start 2022 of $187,664.58. The following is the breakdown of the fund from January 2022-April 2023 (Note: Numbers in parentheses and red are negative):

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balance (January 1. 2022)</td>
<td>$187,664.58</td>
</tr>
<tr>
<td>Income (2022)</td>
<td>6,935.76</td>
</tr>
<tr>
<td>Withdrawals (2022 transfers to VPRF)</td>
<td>40,000.00</td>
</tr>
</tbody>
</table>
Change in value (2022): $(-24,268.10)
Balance (December 31, 2022) $130,332.24
2022 Dollar Weighted Performance (8.35)%
Income (2023 YTD) $574.26
Change in value (2023 YTD) $4,955.44
2023 Dollar Weighted Performance (YTD) 4.24%
Ending Balance (April 28, 2023) $135,861.94

Considering the magnitude of the market downturn in 2022, the Dollar-Weighted Performance is a favorable reflection on the decision-making by the financial advisors at Raymond James.

The Comptroller recommends providing additional donations to the Veterinary Pharmacology Research Foundation (VPRF) over the next 4-6 months in the range of $15,000 - $30,000 to bring the balance of the investment fund to between $100,000-125,000. This maintains a reserve for execution and funding of long-range planning and strategy recommendations and contributes meaningfully to the VPRF.

The Comptroller also filed Non-Profit Federal Income Tax forms for FY 2022 on May 3, 2023 (electronic correspondence on file).

Respectfully submitted,
Scott Brown, DVM, PhD, Dipl ACVCP
AAPVT Comptroller
Report to AAVPT May 2023

The Foundation was formed in 2007 to provide grant funding to support research into new and currently approved medications for combating diseases of companion and food animals, projects that ensure the safety of food products from treated livestock, and training programs for veterinary pharmacologists. The research support from the VPRF has advanced veterinary pharmacology, particularly in areas of unmet needs in veterinary medicine.

The first call for proposals went out in November 2009. To date, VPRF has funded nearly $450,000 in support of veterinary pharmacology research. The Foundation has evaluated over 380 proposals and awarded 25 research grants with 14 funded for dogs, 5 for cats, 1 for swine, and 2 each for equine and dairy cattle. In 2022, we funded our first grant in an exotic species with an important study in Asian elephants. Please see Appendix I for a complete listing of all awarded grants, including the 2022 grants awarded to Drs. Goggs and Vaasjo that were established in honor of two remarkable pharmacologists who we have recently lost, Drs. Lloyd E. Davis and Ralph Claxton.

In 2023, VPRF will continue the strategic partnership with the American Veterinary Medical Foundation (AVMF) to provide the much-needed infrastructure to support proposals, reviews, and grant administration. The Board has approved a 2023 budget to fund up to $15,000 in grants investigating the pharmacokinetics of medications in animals and up to $30,000 to fund grants for general pharmacology studies of drugs in animals.

The 2023 call for proposals will go out on July 15th and will close on September 15th. A final funding decision is expected in January 2024.

VPRF is excited to announce that we have a new program for 2023 which will support our long-term goal of increasing the number and quality of trained veterinary pharmacology researchers. The VPRF Student Fellowship aims to fund a one year, $10,000 fellowship to support training, professional travel, stipends, or other scholarly activities for veterinary pharmacology graduate students. The program is due to launch in the summer of 2023. The guidelines require that the student be a member of AAVPT so that we can also grow the AAVPT membership. Please help us spread the word about this exciting funding opportunity for the next generation of veterinary pharmacologists.

In 2023, we are launching a new fundraising campaign led by Scott Brown to focus on ensuring a legacy for the next generation of veterinary pharmacologists. This includes reaching out more strategically and personally at year end when tax considerations may
be important and creating added emphasis on longer term donations through estate planning and other tax-reducing financial tools for charitable donations. Please reach out to Scott or any board member for more details.

As of March 31, 2023, VPRF has a liquid asset value of $145,410. So far in 2023, $2,967.20 in individual donations from AAVPT and ACVCP members have been received. We have not yet received AAVPT’s 2023 annual pledge which is not expected until after the AAVPT Annual Meeting. We remain grateful for these donations. Please see Appendix II for the financial report from our new Treasurer, Jay Donecker.

To date, AAVPT has been the major source of funding for VPRF. However, we recognize that the generous contributions from this source may not be consistently available at this level in the future. Therefore, the VPRF would like to explore mechanisms whereby the ACVCP could be a stronger contributor to VPRF to help sustain these grant awards that advance veterinary pharmacology.

In July, VPRF board members will attend EAVPT this year and will encourage donations and proposal submission by our European colleagues.

Please see our new website where you can find the latest information on our grant programs and our new donation portal. We owe many thanks to Katherine Palmatier for her excellent talents in creating this site and for her tireless support of VPRF.

The VPRF Board of Directors currently includes Jane Owens (President, representing ACVCP), Anthony Lucas (Secretary, representing AAVPT), Dan Gingerich (representing AAVPT), Joe Gloyd (representing AAVPT), Mark Papich (representing ACVCP), Virginia Fajt (representing AAVPT), Jay Donecker (Treasurer, representing AAVPT), and Scott Brown (representing AAVPT).

VPRF greatly appreciates the continued support and generosity of AAVPT as we work toward our goal of advancing the field of veterinary pharmacology.

Respectfully submitted, Jane G. Owens, President VPRF
Appendix I

VPRF Grant History

2010
The first call for proposals yielded over 30 research proposals for evaluation by the Scientific Review Committee. The first VPRF grant was awarded in June 2010 to Drs. Kenneth Simpson, Melanie Craven, and Belgin Dogan from Cornell University for the development of a novel amikacin delivery method for treatment of E. coli associated with Granulomatous Colitis of Boxer dogs. The researchers received approximately $18,000 for this important work.

2011
In 2011, 12 veterinary pharmacology research proposals were submitted. In November of 2011, a grant of nearly $18,000 was awarded to Drs. Butch KuKanich and Kate KuKanich from Kansas State University for a study to determine the effect of CYP inhibition on tramadol disposition and pharmacological effects in dogs.

2012
In 2012, a total of 20 veterinary pharmacology research proposals were received. Of these, two proposals were selected for funding. Drs. Chen Gilor and Christopher Adin of the Veterinary Clinical Sciences Department at the Ohio State University received approximately $16,000 in funding for evaluating Exenatide extended release in cats. Approximately $4000 was awarded to Drs. Jennifer Myers, Janice Bright, Christopher Orton, Daniel Gustafson and Christine Swardson Olver from the College of Veterinary Medicine & Biomedical Sciences, Colorado State University for evaluation of the pharmacokinetics and pharmacodynamics of Apibaxin in cats. These researchers also received additional funding from ACVIMF for this work.

2013
In 2013, there were 13 grant proposals for evaluation by the Scientific Review Committee. The 2013 Grant was awarded to Drs. Dawn Boothe and Jacqueline Gimmler from the Auburn College of Veterinary Medicine for work to establish terbinafine doses for treatment of canine Malassezia infection. This project was co-funded from the American College of Veterinary Dermatology and the investigators received approximately $14,500 from VPRF.

2014
In 2014, there were 19 grant proposals for evaluation by the Scientific Review Committee. The 2014 Grant was awarded to Dr. Lauren Trepanier of the University of Wisconsin-Madison School of Veterinary Medicine for work to
investigate the Genetic risk for cyclophosphamide toxicity in dogs. The investigator received approximately $17,500 from VPRF.

2015
In 2015, there were 25 grant proposals for evaluation by the Scientific Review Committee. This was a landmark year for VPRF as the organization awarded three grants:

- Dr. Sofia Cerdá-González from Cornell University received approximately $12,700 from VPRF for work to investigate the efficacy of maropitant (Cerenia®) as an adjunct analgesic in dogs.
- Dr. Andrew Mackin from Mississippi State University received approximately $18,000 from VPRF for the pharmacodynamic evaluation of mycophenolate in the dog.
- Drs. M. Katherine Tolbert and Shelly Olin from the University of Tennessee received approximately $15,140 from VPRF for a project to evaluate whether acid suppressants are indicated in cats with chronic kidney disease.

2016
In 2016, there were 39 grant proposals for evaluation by the Scientific Review Committee. This was a record number of submissions and the foundation selected two grants for funding:

- Dr. Claire Fellman from Tufts University received $26,223 in funding for the Pharmacokinetic/Pharmacodynamic Assessment of Differential Responses to Cyclosporine in Atopic Dogs.
- Dr. Katrina R. Viviano, from University of Wisconsin-Madison received $19,280 in funding for a project to evaluate C-Reactive Protein as a Therapeutic Biomarker for Canine Aspiration Pneumonia.

2017
In 2017, there were 52 grant proposals for evaluation by the Scientific Review Committee. This was a record number of submissions and the foundation selected one pharmacokinetic grant and one pharmacology grant for funding:

- Dr. Derek Foster received nearly $30,000 for the Veterinary Pharmacology Research Grant. This work entailed the continuous sampling of the bovine udder by ultrafiltration to assess the pharmacokinetics and pharmacodynamics of intramammary ceftiofur.
- Dr. Duncan X. Lascelles received nearly $15,000 for the Veterinary Pharmacokinetic Research Grant. Dr. Lascelles’ research focuses on the pharmacokinetics of gabapentin in cats by three routes of administration.
2018

In 2018, there were 49 grant proposals for evaluation by the Scientific Review Committee. The foundation selected two pharmacokinetic grants and one pharmacology grant for funding. The 2018 pharmacokinetic grant was named in honor of Dr. Brian Riviere who was the son of Dr. Jim Riviere, Emeritus Professor at North Carolina State University and Kansas State University, one of the pioneers in veterinary pharmacokinetics. His son Brian, was a pharmacist who died suddenly on June 28, 2017, at age 30, due to health complications. Because of their shared interest for pharmacology, the Veterinary Pharmacology Research Foundation has named this research award in honor and memory of Jim’s son Brian.

- Dr. Lauren Trepanier, professor and assistant dean of clinical and translational research at the University of Wisconsin-Madison School of Veterinary Medicine, was the recipient of the Veterinary Pharmacology Research Grant of nearly $12,000 for work to discover why individual dogs respond differently to the drugs azathioprine, cyclophosphamide, cisplatin, lomustine, amiodarone and chlorambucil.
- Dr. John Thomason, associate professor of small animal internal medicine in the Department of Clinical Sciences at Mississippi State College of Veterinary Medicine received nearly $15,000 for research on population pharmacokinetics of subcutaneous enoxaparin in hypercoagulable dogs.
- Dr. Jonathan Foster, internist, Dialysis, Internal Medicine at Friendship Hospital for Animals in Washington, D.C., who was awarded nearly $12,000 for a research on the population pharmacokinetic analysis of enrofloxacin and its active metabolite ciprofloxacin following intravenous injection in cats with reduced kidney function.

2019

In 2019, there were 30 grant proposals for evaluation by the Scientific Review Committee. The foundation selected the following grants for funding:

- Dr. Kara Lascola, associate professor of equine internal medicine, department of clinical sciences at Auburn University’s College of Veterinary Medicine, received the 2019 Veterinary Pharmacokinetic Research Grant. Dr. Lascola’s proposal focused on the evaluation of the pharmacokinetics of nebulized glycopyrrolate administered to asthmatic horses.
- Dr. Monique Pairis-Garcia, associate professor of global production animal welfare, department of population health and pathobiology at North Carolina State University’s College of Veterinary Medicine received the 2019 Veterinary Pharmacology Research Grant. Dr. Pairis-Garcia’s
research aims to identify practical pharmaceutical approaches to mitigate castration pain on commercial swine farms.

2020

In 2020, there were 33 grant proposals for evaluation by the Scientific Review Committee. The foundation selected one pharmacokinetic grant and one pharmacology grant for funding:

- Dr. Amy McLean, Assistant Professor of Teaching Equine Science, UC Davis Animal Science World Donkey Breeds Project received the 2020 Veterinary Pharmacokinetic Research Grant. Dr. McLean’s research is focused on comparing the pharmacokinetics of three flunixin meglumine formulations in donkeys.
- Dr. Andras Komaromy, Professor, Comparative Ophthalmology, Department of Small Animal Clinical Sciences, Michigan State University received the 2020 Veterinary Pharmacology Research Grant. Dr. Komaromy’s research is focused on the Safety and efficacy of topically administered latanoprostene bunod (Vyzulta™) in glaucomatous dogs with ADAMTS10-open-angle glaucoma.

Also in 2020, VPRF partnered with the American College of Veterinary Clinical Pharmacology (ACVCP) to provide a new grant focused on ACVCP Residents. We are grateful to ACVCP for providing $20,000 in funding for this grant as well as additional funding to administer the grant. The ACVCP Resident Grant moved VPRF one step closer to our goal of providing training programs for veterinary pharmacologists.

- Dr. Brent Credille, Associate Professor Food Animal Health and Management Program, Department of Population Health, College of Veterinary Medicine University of Georgia was selected to receive the first ever ACVCP Resident Grant for his project entitled “Disposition of Ampicillin Trihydrate in Healthy Calves and Calves Infected with Mannheimia haemolytica.”

2021

In 2021, there were 29 grant proposals for evaluation by the Scientific Review Committee. The foundation selected two pharmacology grants for funding:

- Dr. Megan Grobman, Assistant Professor of Small Animal Internal Medicine at Auburn University College of Veterinary Medicine, received funding to evaluate the impact of single-dose administration of trazadone on endogenous ACTH and cortisol in healthy dogs.
- Dr. Sarah A. Hamer, Associate Professor of Epidemiology at the Texas A&M College of Veterinary Medicine & Biomedical Sciences (CVMBS), received funding for a study to evaluate the effectiveness of benznidazole
to improve clinical outcomes in client-owned, naturally-infected dogs with Chagas disease, a potentially life-threatening disease of people, dogs, and other animals.

2022
In 2022, there were 30 grant proposals for evaluation by the Scientific Review Committee. The foundation selected one pharmacokinetic grant and one pharmacology grant for funding in honor of two outstanding veterinary pharmacologists who we have recently lost:

- **Dr. Robert Goggs**, Associate Professor at Cornell University College of Veterinary Medicine, is the recipient of the 2022 Honorary Lloyd E. Davis Pharmacology Grant. Dr Goggs received funding to evaluate the pharmacokinetics and pharmacodynamics of direct oral anticoagulants in dogs.

- **Dr. Emma Vaasjo**, a Veterinary Resident at the Saint Louis Zoo, is the recipient of the 2022 Honorary Ralph Claxton Pharmacokinetic Grant. Dr Vaasjo received funding for her project focused on the pharmacokinetics of ganciclovir and valganciclovir in Asian elephants (Elephas maximus).

### Appendix II

**John M. Donecker VMD, MS**
707 Parkway Blvd.
Reidsville, NC 27320
Phone: 336-552-6027
jay.donecker@gmail.com

**TO:** Jane Owens, President Veterinary Pharmacology Research Foundation (VPRF)

**FROM:** Jay Donecker

**DATE:** April 5, 2023

**SUBJECT:** VPRF Treasurer’s Report, for 2022 and 1Q23

**Cc:** Anthony Lucas, Joe Gloyd, Mark Papich, Dan Gingerich, Virginia Fajt, Scott Brown

Please note that this financial update is for 2022 and 1Q23 because the Veterinary Pharmacology Research Foundation (VPRF) IRS accounting period is January 1 through December 31. This update covers VPRF finances from December 31, 2021, to March 31, 2023.
- Liquid assets on December 31, 2021 $229,173.81
- Individual donations 2022 $ 3,181.36
- Expenses (admin.) 2022 ($ 1,475.86)
- Grant expense ($ 44,900.00)
- Returns on investments 2022 ($ 22,765.48)
- Liquid assets on December 31, 2022 $193,213.83
- Individual donation 1Q23 $ 2,967.20
- Expenses (admin) 1Q23 ($ 212.99)
- EAVPT expense ($ 3,466.40)
- Grant expense ($ 49,455.40)
- Returns on investments 1Q23 $ 2,363.04
- Liquid assets as of March 31, 2023, $145,409.68

As of the end of 1Q23, VPRF has a liquid asset value of $145,409.68. The 2022 grants in the amount of $49,455.40 have been disbursed, administered by AVMF. So far, this year individual donations totaling $2,967.20 through AAVPT have been received. We have not received AAVPT’s 2023 annual pledge which is not expected until later this year. Investment returns are very moderate but improved compared to last year’s negative market performance. However, VPRF remains financially healthy, and we anticipate making a $15,000 research award for a PK study and an award of $30,000 for a pharmacology study along with the $10,000 fellowship grant this year.

As of March 28, 2023, following my appointment I have assumed the Treasurer’s role for VPRF. Thanks to Dan Gingerich, all accounts are in order. Going forward, Dan will assume the secondary role I formerly had in which our accounts are reviewed annually as part of our fiduciary responsibility. Dan has set a standard that I hope to match as Treasurer.

The table below details our current finances.

<table>
<thead>
<tr>
<th>Account</th>
<th>31-Dec-22</th>
<th>31-Jan-23</th>
<th>24-Feb-23</th>
<th>30-Mar-23 latest</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank LCNB</td>
<td>$33,750.77</td>
<td>$2,756.21</td>
<td>($34,526.00)</td>
<td>($897.40)</td>
<td>$1,083.58</td>
</tr>
<tr>
<td>American Balanced Fund (ABALX)</td>
<td>$48,931.83</td>
<td>($5,000.00)</td>
<td>$44,588.96</td>
<td>29-Mar-23</td>
<td></td>
</tr>
<tr>
<td>Capital Income Builder (CAIBX)</td>
<td>$39,305.95</td>
<td>($5,000.00)</td>
<td>$39,644.37</td>
<td>29-Mar-23</td>
<td></td>
</tr>
<tr>
<td>Cap World Growth &amp; Income (CWGIX)</td>
<td>$6,792.62</td>
<td>($5,000.00)</td>
<td>$2,008.17</td>
<td>29-Mar-23</td>
<td></td>
</tr>
<tr>
<td>Fundamental Investors (ANCFX)</td>
<td>$33,680.35</td>
<td>($2,500.00)</td>
<td>$27,478.40</td>
<td>29-Mar-23</td>
<td></td>
</tr>
<tr>
<td>The Income Fund of America (AMECX)</td>
<td>$30,752.31</td>
<td>($5,000.00)</td>
<td>$30,606.20</td>
<td>29-Mar-23</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$193,213.83</td>
<td>$2,756.21</td>
<td>($49,526.00)</td>
<td>($3,397.40)</td>
<td>$145,409.68</td>
</tr>
</tbody>
</table>
Combating Illicit Xylazine Act
(H.R. 1839/S. 993)

**KEY POINTS:**

- Xylazine is an important prescription veterinary sedative used to facilitate the safe handling and treatment of many species and is particularly important for use in cattle, horses, zoo/wildlife, and research species.

- Sedation of fractious and large animals with xylazine is critical to keeping people and animals safe. This is an essential drug for safe cattle handling, given there is no practical alternative for sedation in cattle.

- Illicit xylazine (“tranq”) is increasingly being found mixed with illicit narcotic drugs, such as fentanyl, and has been identified as an emerging public health threat.

- Now the U.S. Drug Enforcement Agency (DEA) and lawmakers are looking to address this issue with enforcement tools to target illicit xylazine traffickers.

**What will this bill do?**

The legislation would engage and equip the DEA with tools to combat illicit xylazine trafficking while maintaining veterinarians’ access and ability to legitimately use this critical animal sedative under its current prescription status.

**Specifically:**

- Anyone found importing, manufacturing, or possessing xylazine meant for distribution and use in people would be subject to harsher penalties under the Controlled Substances Act.

- Xylazine for use in non-human species would continue to be overseen by the U.S. Food and Drug Administration (FDA) as a prescription animal drug.

- Any diversion of xylazine from the veterinary supply chain for unlawful use in humans would be subject to harsher penalties under the Controlled Substance Act.

- Manufacturers and distributors of legitimate xylazine would report sales to the DEA through an existing tracking system (ARCOS) that identifies unusual activity or changes in ordering patterns.

- The DEA would submit a report to Congress detailing the prevalence and impacts of illicit xylazine use in the U.S.

**What is the problem?**

- Illicit xylazine has now been found in all 50 states mixed with fentanyl and other narcotics. This potent drug combination poses grave health and safety risks to human users.

- Because xylazine is not an opioid, its effects can’t be reversed with opioid-reversing drugs such as naloxone, complicating the efforts of first responders and emergency physicians.

- Limiting veterinary access to this critical drug will jeopardize animal welfare and human safety.

- This bill will maintain the availability of the product for legitimate veterinary use, minimize supply chain disruption, and preserves its important use for the restraint of livestock and other species.

**Why is AVMA supportive?**

The AVMA fully supports this legislation because it strikes the right balance of protecting our communities from illicit xylazine while preserving veterinary access to this critically important animal drug.

**Status of the bill:**

- On March 28, 2023, H.R. 1839/S. 993 was introduced into Congress by Reps. Jimmy Panetta (D-Calif.) and August Pfluger (R-Texas); and Sens. Catherine Cortez Masto (D-Nev.) and Chuck Grassley (R-Iowa).

**To cosponsor in the House please contact:**
Seamus McKeon (Panetta)
Seamus.McKeon@mail.house.gov

Clara Cargile (Pfluger)
Clara.Cargile@mail.house.gov

**To cosponsor in the Senate please contact:**
Jordan Warner (Cortez Masto)
Jordan_Warner@cornetzmasto.senate.gov

Michael Perkins (Grassley)
Michael_Perkins@judiciary-rep.senate.gov

Contact: Dr. Lindsey Hornickel at lhornickel@avma.org


Updated April 2023
The information and details provided in this report are proprietary and contain information provided in confidence by Wiley to the AAVPT. It is understood that both parties shall treat the contents of this report in strict confidence in perpetuity. © 2023 Wiley
This chart shows the increase in the number of full-text article views for the *Journal of Veterinary Pharmacology and Therapeutics* in the period 2013 to 2022. The total includes usage on Wiley Online Library, PubMed, and other third-party databases. Accesses via Wiley Online Library increased (1.3%) in 2022.

The global reach of the *Journal of Veterinary Pharmacology and Therapeutics* is reflected in its readership, as displayed by this chart showing the origin of full-text article views of the *Journal of Veterinary Pharmacology and Therapeutics* on Wiley Online Library. The darkest shading shows where readership of the *Journal of Veterinary Pharmacology and Therapeutics* is highest.

This chart shows the top 10 countries/regions from which articles in the *Journal of Veterinary Pharmacology and Therapeutics* accessed via Wiley Online Library in 2022, and the percentage each country/region contributed to total usage. All other countries/regions are combined under “Others.”
## Most viewed articles on Wiley Online Library

<table>
<thead>
<tr>
<th>Rank</th>
<th>Author(s)</th>
<th>Article Title</th>
<th>Volume</th>
<th>Issue</th>
<th># of Views</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mohammad-Zadeh, L. et al.</td>
<td>Serotonin: a review</td>
<td>31</td>
<td>3</td>
<td>8,255</td>
</tr>
<tr>
<td>2</td>
<td>Zhou, X. et al.</td>
<td>Current review of isoxazoline ectoparasiticides used in veterinary medicine</td>
<td>45</td>
<td>1</td>
<td>6,107</td>
</tr>
<tr>
<td>3</td>
<td>Burch, D. &amp; Sperling, D.</td>
<td>Amoxicillin—current use in swine medicine</td>
<td>41</td>
<td>3</td>
<td>4,750</td>
</tr>
<tr>
<td>4</td>
<td>Baggot, J.</td>
<td>Pharmacokinetic terms: symbols and units</td>
<td>24</td>
<td>2</td>
<td>4,305</td>
</tr>
<tr>
<td>5</td>
<td>Enomoto, H. et al.</td>
<td>Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs</td>
<td>45</td>
<td>4</td>
<td>2,683</td>
</tr>
<tr>
<td>6</td>
<td>Lees, P. et al.</td>
<td>A history of antimicrobial drugs in animals: Evolution and revolution</td>
<td>0</td>
<td>-</td>
<td>2,115</td>
</tr>
<tr>
<td>7</td>
<td>Sartini, I. &amp; Giorgi, M.</td>
<td>Grapiprant: A snapshot of the current knowledge</td>
<td>44</td>
<td>5</td>
<td>1,933</td>
</tr>
<tr>
<td>8</td>
<td>Davis, J. et al.</td>
<td>Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse</td>
<td>41</td>
<td>3</td>
<td>1,841</td>
</tr>
<tr>
<td>9</td>
<td>Gonzales, A. et al.</td>
<td>Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy</td>
<td>37</td>
<td>4</td>
<td>1,582</td>
</tr>
<tr>
<td>10</td>
<td>Lees, P. et al.</td>
<td>Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib</td>
<td>45</td>
<td>4</td>
<td>1,488</td>
</tr>
</tbody>
</table>

This table includes details of the 10 most-viewed articles of 2022. The average number of views per article published in the *Journal of Veterinary Pharmacology and Therapeutics* in 2022 was 375.

## Top referrers

<table>
<thead>
<tr>
<th>Rank</th>
<th>Referrer Service</th>
<th>% of Views</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Google Search</td>
<td>23.6%</td>
</tr>
<tr>
<td>2</td>
<td>Google Scholar</td>
<td>18.7%</td>
</tr>
<tr>
<td>3</td>
<td>Institutions and Library Services</td>
<td>2.8%</td>
</tr>
<tr>
<td>4</td>
<td>PubMed/PMC</td>
<td>2.4%</td>
</tr>
<tr>
<td>5</td>
<td>Bing</td>
<td>1.1%</td>
</tr>
</tbody>
</table>

Open search continues to play a key role in driving readership. This table shows the top 5 known referrers, and the % of total views resulting from each.

## Article views via Wiley Content Sharing

In 2022, 55 sharing links were generated via the Wiley Content Sharing service, resulting in 9 full-text views. In addition, links shared by authors resulted in 14 views. Links shared by media sites generated a further 10 views.
Author Experience: Submissions

The total number of submissions in 2022 decreased (-30.3%) compared with 2021. This compares with a decrease (-17.0%) across all Wiley journals in the Veterinary Medicine subject area.

The proportion of accepted and rejected articles listed in the year the final decision was taken. The accept rate was 37.7% in 2022, an increase from 33.8% in 2021. This compares with an accept rate of 47.4% across all Wiley journals in the Veterinary Medicine subject area.

This chart shows the top 15 countries/regions ranked by the number of submissions to the Journal of Veterinary Pharmacology and Therapeutics. All submissions counted were submitted in 2022. The remaining countries / regions are grouped into “Others.”
In 2022, the *Journal of Veterinary Pharmacology and Therapeutics* made 71 Editor Driven Referral offers to journals in their network and 11 non-referred rejections were made via our Transfer Desk Assistant. That means 81.19% of the *Journal of Veterinary Pharmacology and Therapeutics*’ rejected papers received an offer of another journal to submit to.

To date, authors have agreed to 93.0% of the Editor Driven transfers that the *Journal of Veterinary Pharmacology and Therapeutics* offered in 2022 and 27.3% of the offers made via the Transfer Desk Assistant.

65 of Editor Driven Referrals offered in 2022 were agreed to by authors and 3 offers from the Transfer Desk Assistant.

These are the most agreed to journals the *Journal of Veterinary Pharmacology and Therapeutics* offered in 2022 broken down by pathway. Currently the structure of data in all EEOs does not allow us to see the exact journals offered, only those agreed to.

<table>
<thead>
<tr>
<th>Journal Name</th>
<th>Pathway</th>
<th>Agreed</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Veterinary Medicine and Science</em></td>
<td>EDR</td>
<td>58</td>
</tr>
<tr>
<td><em>Health Science Reports</em></td>
<td>EDR</td>
<td>7</td>
</tr>
<tr>
<td><em>Fundamental &amp; Clinical Pharmacology</em></td>
<td>TDA</td>
<td>1</td>
</tr>
<tr>
<td><em>Veterinary Medicine and Science</em></td>
<td>TDA</td>
<td>1</td>
</tr>
</tbody>
</table>
Articles are included in the year the decision was made, and data includes all articles, whether or not they were sent out to peer review. The number of days from submission to acceptance in 2022 was a median of 100 days, no change from 100 days in 2021. This compares with a median of 140 in 2022 across all Wiley journals in the Veterinary Medicine subject area.

Articles are included in the year the decision was made, and data excludes articles that were decisioned without peer review. The number of days from submission to acceptance in 2022 was a median of 101 days, down from 113 days in 2021. This compares with a median of 148 in 2022 across all Wiley journals in the Veterinary Medicine subject area.

This chart shows review data for original submissions only for the past five years. Additionally, 208 reviews were claimed on Publons in 2022 by 68 reviewers, a 55.0% uptake.
### Publication trend

<table>
<thead>
<tr>
<th>Year</th>
<th>Volume</th>
<th>Number of Issues</th>
<th>Number of pages (by article)</th>
<th>Number of articles</th>
<th>Median days from receipt at Wiley to Early View publication (min-max)</th>
<th>Median days from receipt at Wiley to online issue publication (min-max)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>45</td>
<td>6</td>
<td>582</td>
<td>67</td>
<td>12 (4-49)</td>
<td>97 (41-335)</td>
</tr>
<tr>
<td>2021</td>
<td>44</td>
<td>6</td>
<td>995</td>
<td>110</td>
<td>21 (9-72)</td>
<td>155 (21-487)</td>
</tr>
<tr>
<td>2020</td>
<td>43</td>
<td>6</td>
<td>635</td>
<td>89</td>
<td>20 (7-84)</td>
<td>118 (35-544)</td>
</tr>
</tbody>
</table>

In 2022, the *Journal of Veterinary Pharmacology and Therapeutics* published 17 open access articles, an increase from 16 in 2021.

### Top 15 author countries/regions

- United States of America: 28
- China: 10
- Turkey: 7
- Thailand: 4
- United Kingdom of Great Britain: 4
- Finland: 2
- France: 2
- Argentina: 1
- Australia: 1
- Belgium: 1
- Brazil: 1
- Germany: 1
- Grenada: 1
- Israel: 1
- Italy: 1
- Others: 4

In 2022, the *Journal of Veterinary Pharmacology and Therapeutics* published 17 open access articles, an increase from 16 in 2021.
## Author Experience: Publication

### Issue publication data for 2022

<table>
<thead>
<tr>
<th>Volume</th>
<th>Issue</th>
<th>Print publication date</th>
<th>Online publication date</th>
<th>Number of pages (by article)</th>
<th>Number of articles</th>
<th>Median number of days from receipt at Wiley to Early View publication (min-max)</th>
<th>Median number of days from receipt at Wiley to online issue publication (min-max)</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 : 1</td>
<td>1</td>
<td>20 Jan 2022</td>
<td>10 Jan 2022</td>
<td>145</td>
<td>15</td>
<td>15 (8-49)</td>
<td>140 (66-335)</td>
</tr>
<tr>
<td>45 : 2</td>
<td>2</td>
<td>16 Mar 2022</td>
<td>06 Mar 2022</td>
<td>81</td>
<td>11</td>
<td>9 (4-19)</td>
<td>91 (83-128)</td>
</tr>
<tr>
<td>45 : 3</td>
<td>3</td>
<td>18 May 2022</td>
<td>08 May 2022</td>
<td>96</td>
<td>11</td>
<td>11 (7-26)</td>
<td>72 (41-122)</td>
</tr>
<tr>
<td>45 : 4</td>
<td>4</td>
<td>22 Jul 2022</td>
<td>11 Jul 2022</td>
<td>90</td>
<td>10</td>
<td>18 (8-46)</td>
<td>96 (66-126)</td>
</tr>
<tr>
<td>45 : 5</td>
<td>5</td>
<td>14 Sep 2022</td>
<td>05 Sep 2022</td>
<td>86</td>
<td>10</td>
<td>14 (9-33)</td>
<td>89 (52-112)</td>
</tr>
<tr>
<td>45 : 6</td>
<td>6</td>
<td>14 Nov 2022</td>
<td>08 Nov 2022</td>
<td>84</td>
<td>10</td>
<td>12 (9-22)</td>
<td>109 (47-152)</td>
</tr>
</tbody>
</table>